Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VJROY
ADC Name
SGN-B6A
Synonyms
PF-08046047; SGN-B6A; SGNB6A; Sigvotatug Vedotin; humanized IgG1 beta-6 monoclonal antibody conjugated to monomethyl auristatin E
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Phase 3
Indication
In total 4 Indication(s)
Lung cancer
Phase 3
Clinical Trial
Gastric cancer
Phase 1
Clinical Trial
Head and neck cancer
Phase 1
Clinical Trial
Oesophageal cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Sigvotatug
  Antibody Info 
Antigen Name
Integrin beta-6 (ITGB6)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
vedotin
DrugMap ID
DMATJL9
TTD ID
DJYD13
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04389632
Phase 1/2
A phase 1 study of SGN-B6A in advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with metastatic or unresectable solid tumors.
Administration Dosage
30 patients in Q1W (0.80, 1.00, and 1.20 mg/kg); 18 patients in 2Q3W (1.20 or 1.25 mg/kg).
Related Clinical Trial
NCT Number NCT04389632  Clinical Status Phase 1/2
Clinical Description A phase 1 study of SGN-B6A in advanced solid tumors.
References
Ref 1 Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol. 2021 39:15_suppl, 2631-2631.